{"id":24722,"date":"2023-06-19T20:42:48","date_gmt":"2023-06-20T00:42:48","guid":{"rendered":"https:\/\/ifintechworld.com\/investing\/big-pharma-vs-washington-an-opportunity-to-buy-merck-co-mrk\/"},"modified":"2023-06-19T20:42:50","modified_gmt":"2023-06-20T00:42:50","slug":"big-pharma-vs-washington-an-opportunity-to-buy-merck-co-mrk","status":"publish","type":"post","link":"https:\/\/ifintechworld.com\/?p=24722","title":{"rendered":"Big Pharma Vs. Washington – An Opportunity To Buy Merck & Co. (MRK)"},"content":{"rendered":"
\n

Warren Buffett states, \u201cUncertainty is the friend of the buyer of long-term values,\u201d and Washington represents a big question mark these days for the pharmaceutical sector.<\/p>\n

After all, news broke on Friday that Bristol Myers Squibb
\n
\n BMY
\n <\/fbs-ticker> <\/strong>has sued Uncle Sam over a Medicare price renegotiation program in the Inflation Reduction Act (IRA) that was passed last August. The pharmaceutical giant\u2019s litigation comes on the heels of similar action from rival Merck & Co.<\/strong>
\n MRK
\n <\/fbs-ticker> , which called the program a \u201csham\u201d and \u201cextortion.\u201d<\/p>\n

Bristol Myers and Merck b0th contend that the law violates the Constitution, with the latter stating it \u201cinvolves neither genuine negotiations nor real agreements.\u201d Rather, Merck argued, \u201cOnce [Health and Human Services] unilaterally selects a drug for inclusion in the program, its manufacturer is compelled to sign an \u2018agreement\u2019 promising to sell the drug to Medicare beneficiaries at whatever \u2018fair\u2019 price the agency dictates, which must represent at least a 25% to 60% discount. If a manufacturer refuses to participate in this \u2018negotiation\u2019 or declines to \u2018agree\u2019 to sell at the mandated price, it incurs a ruinous daily excise tax amounting to multiples of the drug\u2019s daily revenues. And once the Government successfully coerces entry into such an \u2018agreement,\u2019 that manufacturer becomes legally compelled to sell its most valuable products for a fraction of their value, on pain of yet more draconian penalties.\u201d<\/p>\n

Just days after the Merck filing in the District of Columbia, the U.S. Chamber of Commerce filed its own lawsuit against the government in the Southern District of Ohio on grounds that the IRA\u2019s program violated the Constitution\u2019s limit on excessive fines by the government along with due-process protections that might afford companies the opportunity to seek judicial or administrative review of certain government decisions.<\/p>\n

POLITICAL HOT POTATO<\/h2>\n

I acknowledge that drug prices in the U.S. are high and a large third-party buyer should be able to use its purchasing power to negotiate discounts for customers\u2019 best interests. At the same time, I think there are legitimate concerns that such efforts to control prices could adversely impact the level of research and development of lifesaving and life-improving medications.<\/p>\n

<\/fbs-ad><\/p>\n

Far too many compounds don\u2019t pan out, while patent cliffs and the threat of biosimilars often awaits blockbusters. I might also wonder if we would still be in the middle of the pandemic without Merck, Pfizer<\/strong>, Moderna<\/strong>, Johnson & Johnson<\/strong>
\n JNJ
\n <\/fbs-ticker>, Gilead Sciences<\/strong>
\n GILD
\n <\/fbs-ticker> and others developing vaccines and therapeutics.<\/p>\n

Obviously, drug pricing is a political hot potato and the interplay between the companies in which I invest and Washington is not without consequence, but I always endeavor to make logical and unemotional investment decisions.<\/p>\n

I can\u2019t ignore that the new law extends beyond Merck and Bristol Myers to many other major pharmaceutical companies, with the initial drug price reduction process set to begin in September when Uncle Sam identifies the 10 most costly drugs. Following \u201cnegotiations,\u201d the new pricing would go into effect in 2026.<\/p>\n

However, as the Oracle of Omaha points out, also points out, \u201cYou pay a very high price in the stock market for a cheery consensus,\u201d while I am old enough to remember the fantastic returns afforded stocks like MRK following the collapse of the Clinton Administration\u2019s Heath Security Act of 1993 and its attempt to control drug pricing.<\/p>\n

MERCK SHARES ARE UNDERVALUED<\/h2>\n

As Reuters<\/em> pointed out, \u201cMerck\u2019s top-selling drug, cancer immunotherapy Keytruda, could be subject to negotiations as soon as 2028. Last year, Keytruda sales topped $20 billion \u2013 more than a third of Merck\u2019s total sales \u2013 and are expected top $30 billion in 2026, according to analyst estimates.\u201d<\/p>\n

Effects from the IRA and the approach of Keytruda\u2019s loss of exclusivity in 2028 have likely kept a lid on MRK shares, which are down a smidge year to date. But management said at the release of Q1 financial results that it thinks it could add $10 billion of revenue from just cardiology alone over the next decade. And Keytruda\u2019s life could extend well beyond 2028 with potential methods of delivery on the horizon and combination treatments under investigation, as I note the collaborative effort with Moderna to deliver a Personalized Cancer Vaccine alongside Keytruda.<\/p>\n

I continue to think MRK offers growth potential at a reasonable valuation (the NTM P\/E multiple is 15), given a deep pipeline and room to add to existing franchises. The consensus analyst corporate profit estimate stands at $6.98 this year, $8.50 in 2024 and $9.64 in 2025. The company boasts a history of returning cash to shareholders, a diversified revenue stream and solid free-cash-flow generation. The dividend yield is 2.7% and my Target Price is $130.<\/p>\n

<\/h2>\n<\/div>\n

Read the full article here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Warren Buffett states, \u201cUncertainty is the friend of the buyer of long-term values,\u201d and Washington represents a big question mark these days for the pharmaceutical sector. After all, news broke on Friday that Bristol Myers Squibb BMY has sued Uncle Sam over a Medicare price renegotiation program in the Inflation Reduction Act (IRA) that was […]<\/p>\n","protected":false},"author":1,"featured_media":24723,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[239],"tags":[83],"class_list":["post-24722","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-investing","tag-featured"],"yoast_head":"\nBig Pharma Vs. Washington - An Opportunity To Buy Merck & Co. (MRK) | iFintechWorld<\/title>\n<meta name=\"description\" content=\"Warren Buffett states, \u201cUncertainty is the friend of the buyer of long-term values,\u201d and Washington represents a big question mark these days for the\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ifintechworld.com\/?p=24722\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Big Pharma Vs. Washington - An Opportunity To Buy Merck & Co. (MRK) | iFintechWorld\" \/>\n<meta property=\"og:description\" content=\"Warren Buffett states, \u201cUncertainty is the friend of the buyer of long-term values,\u201d and Washington represents a big question mark these days for the\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ifintechworld.com\/?p=24722\" \/>\n<meta property=\"og:site_name\" content=\"iFintechWorld\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-20T00:42:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-20T00:42:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/06\/1687221769_0x0.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"799\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"News Room\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"News Room\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ifintechworld.com\/?p=24722#article\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=24722\"},\"author\":{\"name\":\"News Room\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\"},\"headline\":\"Big Pharma Vs. Washington – An Opportunity To Buy Merck & Co. (MRK)\",\"datePublished\":\"2023-06-20T00:42:48+00:00\",\"dateModified\":\"2023-06-20T00:42:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=24722\"},\"wordCount\":781,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"keywords\":[\"Featured\"],\"articleSection\":[\"Investing\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ifintechworld.com\/?p=24722#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ifintechworld.com\/?p=24722\",\"url\":\"https:\/\/ifintechworld.com\/?p=24722\",\"name\":\"Big Pharma Vs. Washington - An Opportunity To Buy Merck & Co. (MRK) | iFintechWorld\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/#website\"},\"datePublished\":\"2023-06-20T00:42:48+00:00\",\"dateModified\":\"2023-06-20T00:42:50+00:00\",\"description\":\"Warren Buffett states, \u201cUncertainty is the friend of the buyer of long-term values,\u201d and Washington represents a big question mark these days for the\",\"breadcrumb\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=24722#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ifintechworld.com\/?p=24722\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ifintechworld.com\/?p=24722#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ifintechworld.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Big Pharma Vs. Washington – An Opportunity To Buy Merck & Co. (MRK)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ifintechworld.com\/#website\",\"url\":\"https:\/\/ifintechworld.com\/\",\"name\":\"Repay Down\",\"description\":\"Latest Personal Finance News, Tips and Updates\",\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ifintechworld.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ifintechworld.com\/#organization\",\"name\":\"Repay Down\",\"url\":\"https:\/\/ifintechworld.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"width\":558,\"height\":90,\"caption\":\"Repay Down\"},\"image\":{\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\",\"name\":\"News Room\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"caption\":\"News Room\"},\"sameAs\":[\"https:\/\/ifintechworld.com\"],\"url\":\"https:\/\/ifintechworld.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Big Pharma Vs. Washington - An Opportunity To Buy Merck & Co. (MRK) | iFintechWorld","description":"Warren Buffett states, \u201cUncertainty is the friend of the buyer of long-term values,\u201d and Washington represents a big question mark these days for the","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ifintechworld.com\/?p=24722","og_locale":"en_US","og_type":"article","og_title":"Big Pharma Vs. Washington - An Opportunity To Buy Merck & Co. (MRK) | iFintechWorld","og_description":"Warren Buffett states, \u201cUncertainty is the friend of the buyer of long-term values,\u201d and Washington represents a big question mark these days for the","og_url":"https:\/\/ifintechworld.com\/?p=24722","og_site_name":"iFintechWorld","article_published_time":"2023-06-20T00:42:48+00:00","article_modified_time":"2023-06-20T00:42:50+00:00","og_image":[{"width":1200,"height":799,"url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/06\/1687221769_0x0.jpg","type":"image\/jpeg"}],"author":"News Room","twitter_card":"summary_large_image","twitter_misc":{"Written by":"News Room","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ifintechworld.com\/?p=24722#article","isPartOf":{"@id":"https:\/\/ifintechworld.com\/?p=24722"},"author":{"name":"News Room","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61"},"headline":"Big Pharma Vs. Washington – An Opportunity To Buy Merck & Co. (MRK)","datePublished":"2023-06-20T00:42:48+00:00","dateModified":"2023-06-20T00:42:50+00:00","mainEntityOfPage":{"@id":"https:\/\/ifintechworld.com\/?p=24722"},"wordCount":781,"commentCount":0,"publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"keywords":["Featured"],"articleSection":["Investing"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ifintechworld.com\/?p=24722#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ifintechworld.com\/?p=24722","url":"https:\/\/ifintechworld.com\/?p=24722","name":"Big Pharma Vs. Washington - An Opportunity To Buy Merck & Co. (MRK) | iFintechWorld","isPartOf":{"@id":"https:\/\/ifintechworld.com\/#website"},"datePublished":"2023-06-20T00:42:48+00:00","dateModified":"2023-06-20T00:42:50+00:00","description":"Warren Buffett states, \u201cUncertainty is the friend of the buyer of long-term values,\u201d and Washington represents a big question mark these days for the","breadcrumb":{"@id":"https:\/\/ifintechworld.com\/?p=24722#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ifintechworld.com\/?p=24722"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ifintechworld.com\/?p=24722#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ifintechworld.com\/"},{"@type":"ListItem","position":2,"name":"Big Pharma Vs. Washington – An Opportunity To Buy Merck & Co. (MRK)"}]},{"@type":"WebSite","@id":"https:\/\/ifintechworld.com\/#website","url":"https:\/\/ifintechworld.com\/","name":"Repay Down","description":"Latest Personal Finance News, Tips and Updates","publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ifintechworld.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ifintechworld.com\/#organization","name":"Repay Down","url":"https:\/\/ifintechworld.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","width":558,"height":90,"caption":"Repay Down"},"image":{"@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61","name":"News Room","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","caption":"News Room"},"sameAs":["https:\/\/ifintechworld.com"],"url":"https:\/\/ifintechworld.com\/?author=1"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/24722","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=24722"}],"version-history":[{"count":1,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/24722\/revisions"}],"predecessor-version":[{"id":24724,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/24722\/revisions\/24724"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/media\/24723"}],"wp:attachment":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=24722"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=24722"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=24722"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}